Merck KGaA (OTCMKTS:MKGAF) Stock Falls 6% – Should You Sell?

Merck KGaA (OTCMKTS:MKGAF) shares fell 6% on Wednesday. The company traded as low as $154.1260 and last traded at $154.1260. 76 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 632 shares. The stock had previously closed at $163.94.

Merck KGaA Stock Down 6.0%

The stock has a fifty day moving average price of $161.08 and a 200-day moving average price of $150.70. The firm has a market cap of $19.92 billion, a PE ratio of 23.53 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31.

Institutional Investors Weigh In On Merck KGaA

Hedge funds have recently modified their holdings of the stock. North Star Asset Management Inc. purchased a new stake in shares of Merck KGaA during the second quarter valued at approximately $1,411,000. MASTERINVEST Kapitalanlage GmbH acquired a new stake in Merck KGaA during the 2nd quarter valued at $4,896,000. Ames National Corp purchased a new stake in Merck KGaA during the 2nd quarter worth $1,009,000. Elefante Mark B purchased a new stake in Merck KGaA during the 2nd quarter worth $617,000. Finally, Pinnacle Holdings LLC acquired a new position in Merck KGaA in the 2nd quarter worth $1,487,000. 0.10% of the stock is currently owned by hedge funds and other institutional investors.

About Merck KGaA

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. Merck KGaA is separate from the U.S.-based Merck & Co, Inc, although the two companies share historical roots.

The company operates through three business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, chemicals and bioprocessing technologies used by pharmaceutical, biotechnology and academic customers.